12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers

• SeaStar Medical Holding (NASDAQ:ICU) shares increased by 68.0% to $0.99 during Thursday's pre-market session. The company's market cap stands at $13.1 million. As per the press release, Q1 earnings came out 3 days ago.
• Alimera Sciences (NASDAQ:ALIM) shares increased by 36.89% to $2.82. The company's market cap stands at $20.8 million. The company's, Q1 earnings came out 3 days ago.
• Enveric Biosciences (NASDAQ:ENVB) stock moved upwards by 36.84% to $2.08. The company's market cap stands at $4.3 million. As per the press release, Q1 earnings came out 3 days ago.
• Hillstream BioPharma (NASDAQ:HILS) stock increased by 18.28% to $0.49. The market value of their outstanding shares is at $8.2 million.
• Armata Pharmaceuticals (AMEX:ARMP) shares moved upwards by 16.79% to $1.46. The market value of their outstanding shares is at $52.7 million.
• Microbot Medical (NASDAQ:MBOT) stock rose 15.12% to $1.37. The market value of their outstanding shares is at $11.1 million.

Losers

• AgeX Therapeutics (AMEX:AGE) stock decreased by 24.2% to $0.4 during Thursday's pre-market session. The market value of their outstanding shares is at $15.1 million. As per the news, the Q1 earnings report came out 4 days ago.
• Motus GI Hldgs (NASDAQ:MOTS) shares declined by 16.33% to $0.84. The company's market cap stands at $3.9 million.
• Phio Pharma (NASDAQ:PHIO) shares fell 9.31% to $3.41. The market value of their outstanding shares is at $5.1 million.
• Vapotherm (NYSE:VAPO) stock declined by 8.15% to $0.55. The market value of their outstanding shares is at $25.4 million.
• Impel Pharmaceuticals (NASDAQ:IMPL) shares decreased by 8.01% to $1.15. The market value of their outstanding shares is at $27.3 million. As per the press release, Q1 earnings came out 4 days ago.
• NanoString Technologies (NASDAQ:NSTG) stock declined by 7.64% to $7.86. The market value of their outstanding shares is at $372.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.